Ovid – $75 Million IPO

Palo Alto – June 12, 2017 – Cooley advised Ovid on its $75 million initial public offering of 5,000,000 shares of common stock.

Ovid, which now trades on The NASDAQ Global Select Market as “OVID,” is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders.

This transaction follows a series of life sciences IPOs that Cooley advised on in the first half of the year.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Laura Berezin  Partner Palo Alto
Div Gupta  Partner New York
Jaime L. Chase  Partner Washington, DC
Sara Semnani  Partner Los Angeles
Jeramie Perez  Senior Paralegal Palo Alto
Jason Minio  Senior Paralegal Boston
Natasha Leskovsek  Of Counsel Washington, DC
Phil Mitchell  Partner New York
Ivor Elrifi  Partner New York, Boston
Heidi A. Erlacher  Partner in Charge – Boston Boston
David Walsh  Partner Reston
Mary Maher Lewis  Associate Reston
Mike Faber  Retired Partner San Francisco
Francis Wheeler  Partner Colorado